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Abstract
Objectives: Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with
impaired patient functioning and reductions in health-related quality of life (HRQL). The present
study describes the impact of MDD on patients' HRQL and examines preference-based health state
differences by patient features and clinical characteristics.
Methods: 95 French primary care practitioners recruited 250 patients with a DSM-IV diagnosis of
MDD for inclusion in an eight-week follow-up cohort. Patient assessments included the
Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global Impression of Severity
(CGI), the Short Form-36 Item scale (SF-36), the Quality of Life Depression Scale (QLDS) and the
EuroQoL (EQ-5D).
Results: The mean EQ-5D utility at baseline was 0.33, and 8% of patients rated their health state
as worse than death. There were no statistically significant differences in utilities by demographic
features. Significant differences were found in mean utilities by level of disease severity assessed by
CGI. The different clinical response profiles, assessed by MADRS, were also revealed by EQ-5D at
endpoint: 0.85 for responders remitters, 0.72 for responders non-remitter, and 0.58 for non-
responders. Even if HRQL and EQ-5D were moderately correlated, they shared only 40% of
variance between baseline and endpoint.
Conclusions: Self-reported patient valuations for depression are important patient-reported
outcomes for cost-effectiveness evaluations of new antidepressant compounds and help in further
understanding patient compliance with antidepressant treatment.
Introduction
Major depressive disorder (MDD) is common in primary
care patients [1] with a lifetime prevalence rate in the
French population of 10–25% in women and 5–12% in
men [2]. Depression is associated with marked decreases
in functioning, well being and health-related quality of
life (HRQL) [3,4], and an increases in disability days [5],
use of health services and overall societal costs [6]. Anti-
depressant treatments are effective in reducing depression
Published: 05 May 2004
Health and Quality of Life Outcomes 2004, 2:20
Received: 08 March 2004
Accepted: 05 May 2004
This article is available from: http://www.hqlo.com/content/2/1/20
© 2004 Sapin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.
Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
Page 2 of 8
(page number not for citation purposes)
severity [7,8] and in increasing patient functioning and
HRQL [9,10].
The Washington Panel on Cost-Effectiveness in Health
and Medicine recommended the use of HRQL in the eval-
uation of health care interventions [11]. For this purpose,
HRQL measurement needs to express patient health status
on a scale where perfect health and death are valued 1 and
0 respectively. When such quality of life data are com-
bined with corresponding data on the quantity of life,
then the consequences of treatment are measured in units
of Quality-Adjusted Life Years (QALYs) [12]. Where
QALYs are calculated for social decision making purposes
then the HRQL measures used to make the quality adjust-
ment should be based on the preferences of the popula-
tion as a whole. Such social preferences are only available
for a limited number of HRQL measures and for a limited
number of countries. EQ-5D is one such measure that has
been calibrated in this way.
Studies of physical illnesses have suggested that patient's
values for their own health state affect decisions concern-
ing treatment and its outcomes [13-15]. Several studies
focused on establishing utility scores for a variety of
health states in various mental illnesses, including schizo-
phrenia [16], depression in primary care [17], temporary
states of depression [18,19] and treatment-related side
effects [20,21]. Health states in depression have been
characterised by the presence or absence of symptoms,
and depressed patients are usually categorised as respond-
ers and remitters using classical rating scales [22]. As
responders sometimes present residual depressive symp-
toms, we classify patients as "Responder remitters",
"Responders non-remitter" and "Non-responders".
The objectives of this paper are to describe the impact on
HRQL of patients with MDD treated in a primary care set-
ting, and to examine variations in terms of patients'
demographic and clinical characteristics.
Material and methods
Design and patient sample
This national, multicentre, prospective, non-comparative
cohort study was designed so as to reproduce the guide-
lines for management of depression in primary care. The
scheduled follow-up period was two months, with assess-
ments at baseline (D0), four weeks later (D28) and eight
weeks later (D56).
The patients included in this study were recruited from an
outpatient population, aged 18 and older, who consulted
general practitioners for a new episode of MDD according
to the DSM-IV [23]), and who were not treated with any
antidepressant before inclusion. Patients whose symp-
tomatology suggested schizophrenia or other psychotic
symptoms, according to DSM-IV, were not included in
this study. According to their experience and daily prac-




Patient profiles were created at baseline by recording age,
gender, lifestyle, place of residence, socio-professional cat-
egory and current professional status.
Clinical measures
Physicians assessed the severity of depressive symptoms
using the Montgomery-Asberg Depression Rating Scale
(MADRS) [24] and the Clinical Global Impression of
Severity (CGI-S) scale. The CGI was rated by physicians on
a seven-point Likert scale ranging from 1 = "Normal, not
ill at all" to 7 = "Among the most ill patients".
Qualitative outcomes derived from rating scales, like
response to treatment or remission, are usually used in
both clinical trials and economic evaluations of new anti-
depressant agents [22]. Using MADRS scores at D56,
patients were classified into two groups: those that had
scores lower or equal to 12 were considered as "Remit-
ters", the others were considered as "Non-remitters".
Patients who had a decrease of at least 50% in relation to
baseline score were considered as "Responder", whereas
the others were "Non-responders". These two patients
groupings led to the creation of three mutually exclusive
groups: "Responder remitters", "Responders non-remit-
ter" and "Non-responders".
Patient Reported Outcomes
The outcome measures used in this study were the 36-
item Short-Form Health Survey (SF-36), the Quality of
Life in Depression Scale (QLDS) and the EQ-5D.
The SF-36 is a generic HRQL measure consisting of eight
dimensions assessing physical functioning (PF), role lim-
itations due to physical problems (RP), bodily pain (BP),
general health (GH), vitality (VT), mental health (MH),
role limitations due to emotional problems (RE) and
social functioning (SF) [25]. Two summary scores also
assess both physical (PCS) and mental (MCS) facets [26].
All scale scores range from 0 (the worst HRQL) to 100 (the
best HRQL).
The QLDS is a 34-item depression-specific HRQL instru-
ment that assesses the ability and capacity of individuals
to satisfy their daily needs [27,28]. Each item is answered
by Yes or No. An overall HRQL score is obtained by sum-
ming the 34 items. The results range from 0 (the highest
HRQL) to 34 (the lowest HRQL).
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EQ-5D is a generic measure of HRQL in which health sta-
tus is defined in terms of 5 dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion [29]. Each dimension has three qualifying levels of
response roughly corresponding to 'no problems', 'some
difficulties/problems', and 'extreme difficulties'. EQ-5D
defines a total of 243 unique health states. The impor-
tance of each of these states can be determined in a
number of different ways. For the purpose of cost-utility
analysis and other situations where the consequences of
treatment are measured in terms of QALYs, these weights
are typically established using utility measurement tech-
niques such as Standard Gamble or Time Trade-Off (TTO)
[12]. For the purposes of this present study, TTO weights
elicited from a large national survey of the UK population
were used [30]. Information collected using EQ-5D can be
reported in terms of its individual dimensions and as a
single index score (EQ-5DST).
Data analysis
Continuous variables were expressed by means and stand-
ard deviations, whereas categorical data were presented
using frequency and percentage. The scales were scored
using scoring algorithms described by the scale designers.
Student's t-tests, ANOVA, Mann-Whitney, or Kruskal-Wal-
lis tests were performed when appropriate to compare
mean scores across subgroups. Regression analyses were
used to examine the relationships between differences in
the utility-weighted EQ-5DST and demographics, clinical
response and HRQL measures. Several selection proce-
dures (backward, stepwise) were tested in order to check
the robustness of the model. The impact of each predictor
was assessed with estimates and their 95% confidence
interval. The data were analysed using the SAS software
version 8.2. For all tests, the type I error was set to 0.05.
Results
Sample characteristics
Ninety-five physicians enrolled 250 patients between May
and November 2002. Patient age ranged from 18 to 92
years, with a mean of 44.2 ± 14.1 years (mean ± standard
deviation). The sex ratio (males/females) was 0.4. The
mean MADRS score was 32.7 ± 7.7, ranging from 13 to 53.
This high level of severity was also revealed by the CGI:
about 85% of patients were rated "markedly ill" or more
severely. The demographic and clinical characteristics of
the sample are reported in Table 1.
Among the 250 included patients, 24 were lost to follow-
up (9.6%). Their sociodemographics and clinical charac-









Intermediate profession 44 17.9
Employee 78 31.7
Manual labourer 19 7.7
Retired 27 11.0
Other 36 14.6
Place of residence c
Urban area 185 74.3
Rural area 64 25.7
CGI-Severity at baseline
First signs 0 0.0
Slightly ill 6 2.4
Moderately ill 36 14.4
Markedly ill 173 69.2
Seriously ill 35 14.0
Clinical response
Responder remitters 144 64.3
Responders non-remitter 34 15.2
Non-responders 46 20.5
a missing value = 1; b missing values = 4; c missing values = 26.
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teristics were not significantly different from those of the
226 completers, so that all subsequent analyses were per-
formed on the completers sub-sample.
Impact of MDD on HRQL
At baseline, the mean QLDS score was 20.8 ± 5.8, ranging
from 5 to 31. The mean SF-36 dimension scores for the
total sample were: PF 69.0 ± 24.5, RP 22.4 ± 30.7, BP 52.0
± 23.5, GH 38.3 ± 17.3, VT 22.2 ± 13.1, MH 24.5 ± 12.1,
RE 9.1 ± 21.3 and SF 30.2 ± 17.1. The mean SF-36 sum-
mary scores were PCS 43.6 ± 9.2 and MCS 21.1 ± 6.6. The
mean EQ-5DST score was 0.33 ± 0.25, ranging between -
0.59 and 0.85. It was noteworthy that 8% of the study
population had an EQ-5DST score of worse than death, i.e.
less than zero.
During follow-up, all the dimensions rated improved
(Table 2). The mean EQ-5DST scores were 0.68 ± 0.24
(range: [-0.11; 1.00]) and 0.78 ± 0.21 (range: [-0.08;
1.00]) at weeks 4 and 8, respectively.
Comparison of EQ-5DST by demographic and clinical 
features
No significant differences were found in EQ-5DST by
demographics characteristics (Table 3): men and women
reported the same preference-based score at baseline
(0.32 ± 0.22 vs. 0.32 ± 0.26, respectively) and their scores
increased in a similar manner during follow-up. Younger
patients reported higher utility scores than older patients
at baseline, day 28 and day 56, although this pattern was
not statistically significant.
Significant differences in EQ-5DST were found by disease
severity level assessed by CGI-S, with more severe patients
having lower weighted index scores. At baseline, a mean
difference of 0.12 was observed between "slightly/moder-
ately ill" and "markedly ill" patients (p < 0.05), and 0.18
between "markedly ill" and "seriously ill" patients (p <
0.001). At the end of the follow-up, a mean difference of
0.12 was observed between patients with "first signs of ill-
ness" and "slightly/moderately ill" patients (p < 0.001).
"Slightly/moderately ill" and "markedly ill" patients had
EQ-5DST scores that differed 0.30 on average (p < 0.001).
A mean difference of 0.14 between "markedly ill" patients
and "seriously ill" patients was found (p < 0.05).
Comparison of EQ-5DST by clinical response
Clinical response, defined by MADRS scores, revealed sta-
tistically significant differences between mean EQ-5DST
scores at baseline (p < 0.01), D28 (p < 0.001) and D56 (p
< 0.001) (Table 4).
At baseline, an overall significant difference was found in
comparing the three groups, with a mean difference of
0.14 observed between "Responder remitters" and
"Responder non-remitters" (p < 0.01). During the study
period, EQ-5DST scores increased in all groups of clinical
response. At the end of the follow-up, a statistically signif-
icant mean difference of 0.14 was observed between
Table 2: EQ-5D dimension scores at baseline, D28 and D56
Baseline D28 D56
N % N % N %
Mobility
No difficulties 166 73.5 192 85.0 207 91.6
Some difficulties 58 25.6 34 15.0 19 8.4
Extreme difficulties 2 0.9 0 0.0 0 0.0
Self-care
No difficulties 186 82.3 214 94.7 216 95.6
Some difficulties 38 16.8 12 5.3 10 4.4
Extreme difficulties 2 0.9 0 0.0 0 0.0
Usual activities
No difficulties 56 24.8 133 58.9 172 76.1
Some difficulties 150 66.4 92 40.7 53 23.5
Extreme difficulties 20 8.8 1 0.4 1 0.4
Pain/Discomfort
No difficulties 54 23.9 114 50.4 135 59.8
Some difficulties 153 67.7 108 47.8 90 39.8
Extreme difficulties 19 8.4 4 1.8 1 0.4
Anxiety/Depression
No difficulties 2 0.9 27 11.9 72 31.9
Some difficulties 48 21.2 155 68.6 133 58.8
Extreme difficulties 176 77.9 44 19.5 21 9.3
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"Responder remitters" and "Responders non-remitter" (p
< 0.001). "Responders non-remitter" and "Non-respond-
ers" had EQ-5DST scores that significantly differed by 0.14
on average (p < 0.05).
Comparison of Patient Reported Outcomes
At each visit, EQ-5DST scores were compared with SF-36
dimension, SF-36 summary and QLDS scores (Table 5) by
computing correlation coefficients. The correlation
between EQ-5DST score and the Mental Health dimension
of the SF-36 was the highest observed, whatever the
assessment (DO: r = 0.49; D28: r = 0.56; D56: r = 0.63). At
baseline, Pearson correlation coefficients were always
greater than 0.30, except for the role-physical and role-
emotional dimensions.
The QLDS was significantly correlated with the EQ-5DST
scores, ranging from -0.43 at baseline to -0.68 at the end
of the follow-up period.
Multivariate analysis
An ordinary least-square regression analysis to predict EQ-
5DST using demographic features, clinical and HRQL evo-
lution only explained 40% of the variance in the weighted
index scores. The statistically significant predictors in the
regression model were differences in Physical Function-
ing, Bodily Pain, General Health and Mental Health
(Table 6).
Discussion
This study evaluated the usefulness of EQ-5D in assessing
health status of primary care patients with major depres-
sive disorder.
The sampling of our study is representative of the primary
care depressed population in France [2]. 8% of the
patients rated their health state as worse than death. This
result is not surprising given the relationship between
depression and suicide [31,32]. Despite different
approaches to measuring health state utilities using stand-
ard gamble, time trade-off or rating scales, the findings of
Table 3: Differences on utility score by demographic and clinical characteristics
Baseline D28 D56
Mean ± SD p Mean ± SD p Mean ± SD p
Gender 0.94 0.48 0.70
Male 0.32 ± 0.22 0.66 ± 0.24 0.79 ± 0.20
Female 0.32 ± 0.26 0.68 ± 0.25 0.77 ± 0.21
Age group 0.76 0.12 0.64
≤30 years 0.35 ± 0.23 0.76 ± 0.24 0.81 ± 0.23
31–65 years 0.32 ± 0.24 0.66 ± 0.25 0.77 ± 0.21




Urban area 0.31 ± 0.25 0.65 ± 0.25 0.77 ± 0.21
Rural area 0.34 ± 0.25 0.75 ± 0.22 0.81 ± 0.19
CGI-Severity <0.001 <0.001 <0.001
First signs -- 0.80 ± 0.14 0.86 ± 0.13
Slightly/
Moderately ill
0.45 ± 0.22 0.66 ± 0.23 0.74 ± 0.19
Markedly ill 0.33 ± 0.24 0.40 ± 0.26 0.44 ± 0.27
Seriously ill 0.15 ± 0.21 0.14 ± 0.14 0.30 ± 0.27
Table 4: Utility scores and clinical response during the study period
Baseline D28 D56
Mean ± SD p Mean ± SD p Mean ± SD p
Clinical response <0.01 <0.001 <0.001
Responder remitters 0.35 ± 0.24 0.76 ± 0.18 0.85 ± 0.13
Responders non-remitter 0.21 ± 0.25 0.54 ± 0.26 0.72 ± 0.20
Non-responders 0.30 ± 0.27 0.54 ± 0.30 0.58 ± 0.28
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our study agree with those previously reported: the base-
line mean utility of an untreated depression was 0.33,
compared to 0.30 for Revicki [21] and 0.32 for Bennett
[33]. Patient-rated EQ-5DST scores after the eight-week fol-
low-up period was 0.78, which is comparable to utilities
reported in other studies (0.79 [33]; 0.74 [21]; 0.76 [34];
0.70 [35]). The main interest is that EQ-5DST values are
easy to collect in large sample surveys due to the brevity of
EQ-5D classification system with its 5 dimensions and 3
levels.
No differences in EQ-5DST utilities were observed by
demographic characteristics, which is comparable to pre-
vious results in depressed patients [21,34,35]. More
severely depressed patients reported utilities that were
0.30 points lower than less severely depressed patients at
baseline. Several researchers have suggested that differ-
ences in utility greater than 0.05 are clinically important
[12,36]. These findings may reflect clinically important
differences.
As demonstrated in previous studies [21,37], we found
that the EQ-5DST score and other HRQL measures shared
only about 40% of variance. Utilities measure a patient's
preference for their health state, while HRQL scales assess
the patient's report of their functioning and well-being.
Although these two concepts are related they are not iden-
tical [38], and measuring both may lead to a better under-
standing of reasons for non-compliance to treatment
regimens.
There are several limitations that need to be considered
when interpreting the results of this study. First, the study
does not take into account the antidepressant prescribed
or their side effects, which may influence patients' ratings
[21,39]. Second, the concomitant impact of depression
and chronic medical conditions could not be examined in
this sample. It is likely that the health state utilities of
patients with depression, in addition to a chronic medical
disease would be significantly reduced [17]. Lastly, a lim-
itation of the analysis presented in this study relates to the
source of the utility weights used to compute the EQ-5DST.
Given that this was a national study conducted in France
it may have been better to use social preference values
based on the French population. Unfortunately, at the
time of writing these values were not available for EQ-




Physical Functioning 0.39*** 0.42*** 0.45***
Role-Physical Limitations 0.28*** 0.51*** 0.47***
Bodily Pain 0.37*** 0.53*** 0.53***
General Health 0.47*** 0.54*** 0.58***
Vitality 0.45*** 0.54*** 0.59***
Mental Health 0.49*** 0.56*** 0.63***
Role-Emotional Limitations 0.26*** 0.46*** 0.49***
Social Functioning 0.44*** 0.54*** 0.59***
Physical Composite Summary 0.42*** 0.51*** 0.50***
Mental Composite Summary 0.34*** 0.49*** 0.58***
Quality of Life for Depression Scale -0.43*** -0.59*** -0.68***
*** p < 0.001
Table 6: Contributors of the difference in EQ-5DST during the study period
Parameter estimate Standard error p-value 95% Confidence 
Interval
Intercept 0.1971 0.0291 <0.001 [0.1396–0.2546]
Physical Functioning 0.0019 0.0007 <0.01 [0.0005–0.0033]
Bodily Pain 0.0016 0.0007 <0.05 [0.0001–0.0030]
General Health 0.0030 0.0009 <0.01 [0.0011–0.0048]
Mental Health 0.0044 0.0009 <0.001 [0.0027–0.0061]
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5DST. Weights were therefore adopted from a major UK
study that provided the most robust technical estimates
widely used in the evaluation of EQ-5DST in countries that
lack their own national reference data.
Utility scores are needed for calculating QALYs, which are
used as indicators of effectiveness or outcome in eco-
nomic evaluations [35,36,40]. It is debatable whether or
not patient or general population utilities should be used
in cost-effectiveness studies [40]. Nevertheless, patients
with experience in the disease may be the best providers
of health state preference data. Cost-effectiveness studies
are required to help clinicians and health care decision-
makers in determining the impact of new antidepressants
on both patient outcomes and medical or overall societal
costs. Understanding patient preferences for depression
outcomes is important for economic evaluations of new
antidepressants, as well as for understanding patient
behaviour and compliance to antidepressant regimens.
Such a measure can be applied to cost-utility analyses
either within clinical decision modelling studies or within
prospective, randomised clinical trials and offers addi-
tional scope for the analysis and reporting of data derived
from clinical trials of new compounds.
Acknowledgment
Funding for this study was provided by H. Lundbeck A/S.
References
1. Williams JW Jr, Kerber CA, Mulrow CD, Medina A, Aguilar C:
Depressive disorders in primary care: prevalence, functional
disability and identification. J Gen Intern Med 1995, 10:7-12.
2. Le Pape A, Lecomte T: Prévalence et prise en charge de la
dépression. Paris: Centre de Recherche en Economie de la Santé 1999.
3. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K: Func-
tioning and well-being outcomes of patients with depression
compared with chronic general medical illnesses. Arch Gen
Psychiatry 1995, 52:11-9.
4. Saarijarvi S, Salminen JK, Toikka T, Raitasalo R: Health-related
quality of life among patients with major depression. Nord J
Psychiatry 2002, 56:261-4.
5. Lecrubier Y: The burden of depression and anxiety in general
medicine. J Clin Psychiatry 2001, 62:4-9.
6. Goff VV: Depression: a decade of progress, more to do. NHPF
Issure Brief 2002, 786:1-14. (Nov 22)
7. Nierenberg AA: Current perspectives on the diagnosis and
treatment of major depressive disorder. Am J Manag Care 2001,
7:S353-66.
8. Brown C, Schulberg HC, Prigerson HG: Factors associated with
symptomatic improvement and recovery from major
depression in primary care patients. Gen Hosp Psychiatry 2000,
22:242-50.
9. Revicki DA, Simon GE, Chan K, Katon W, Heiligenstein J: Depres-
sion, health-related quality of life, and medical cost out-
comes of receiving, recommended levels of antidepressant
treatment. J Fam Pract 1998, 47:446-52.
10. Reynolds CF 3rd: Treatment of major depression in late life: a
life cycle perspective. Psychiatr Q 1997, 68:221-46.
11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recom-
mendations of the Panel on Cost-Effectiveness in Health and
Medicine. JAMA 1996, 276:1253-8.
12. Bennett KJ, Torrance GW: Measuring health state preferences
and utilities: rating scale, time trade-off and standard gam-
ble techniques. In: Quality of Life and Pharmacoeconomics in Clinical
Trials 2nd edition. Edited by: Spilker B. Philadelphia: Lipincott-Raven;
1996. 
13. de Boer AG, Stalmeier PF, Sprangers MA, de Haes JC, van Sandick JW,
Hulscher JB, van Lanschot JJ: Transhiatal vs extended transtho-
racic resection in oesophageal carcinoma: patients' utilities
and treatment preferences. Br J Cancer 2002, 86:851-7.
14. Tosteson AN, Hammond CS: Quality-of-life assessment in oste-
oporosis: health-status and preferenced-based measures.
Pharmacoeconomics 2002, 20:289-303.
15. Smith DS, Krygiel J, Nease RF Jr, Sumner W 2nd, Catalona WJ:
Patient preferences for outcomes associated with surgical
management of prostate cancer. J Urol 2002, 167:2117-22.
16. Chouinard G, Albright PS: Economic and health state utility
determinations for schizophrenic patients treated with risp-
eridone or haloperidol. J Clin Psychopharmacol 1997, 17:298-307.
17. Wells KB, Sherbourne CD: Functioning and utility for current
health status of patients with depression or chronic medical
conditions in managed, primary care practices. Arch Gen
Psychiatry 1999, 56:897-904.
18. Bennett KJ, Torrance GW, Boyle MH, Guscott R: Cost-utility anal-
ysis in depression: the McSad utility measure for depression
health state. Psychiatr Serv 2000, 51:1171-6.
19. Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, Lanctot K:
Utility scores of symptom profiles in major depression. Psychi-
atry Res 2002, 110:189-97.
20. Lenert LA, Morss S, Goldstein MK, Bergen MR, Faustman WO, Gar-
ber AM: Measurement of the validity of utility elicitations per-
formed by computerized interview. Med Care 1997, 35:915-20.
21. Revicki DA, Wood M: Patient-assigned health state utilities for
depression-related outcomes: differences by depression
severity and antidepressant medications. J Affect Disord 1998,
48:25-36.
22. Committee for Proprietary Medicinal Products: Note for Guidance
on Clinical Assessment of Medicinal Products in the Treat-
ment of Depression. London: EMEA 2002.
23. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders. Washington DC: American Psychiatric
Association 41994.
24. Montgomery SA, Asberg M: A New Depression Scale Designed
to be Sensitive to Change. Br J Psychiatry 1979, 134:382-9.
25. Leplège A, Ecosse E, Verdier A, Perneger TV: The French SF-36
Health Survey: translation, cultural adaptation and prelimi-
nary psychometric evaluation. J Clin Epidemiol 1998, 51:1013-23.
26. Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier
J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M, Thunedborg K:
The equivalence of SF-36 summary health scores estimated
using standard and country-specific algorithms in 10
countries. J Clin Epidemiol 1998, 51:1167-70.
27. Hunt SM, McKenna SP: The QLDS, a scale for the measurement
of quality of life in depression. Health Policy 1992, 22:307-19.
28. McKenna SP, Doward LC, Kohlmann T, Mercier C, Niero M, Paes M,
Patrick D, Ramirez N, Thorsen H, Whalley D: International devel-
opment of the Quality of Life in Depression Scale (QLDS). J
Affect Disord 2001, 63:189-99.
29. EuroQoL Group: EuroQoL – a new facility for the measure-
ment of health-related quality of life. Health Policy 1990,
16:199-208.
30. Dolan P, Gudex C, Kind P, Williams A: A social tariff for Euro-
QoL: Results from a UK General Population Survey. University
of York: Center for Health Economics 1995.
31. Kohn Y, Zislin J, Agid O, Hanin B, Troudard T, Shapira B, Bloch M,
Gur E, Ritsner M, Lerer B: Increased prevalence of negative life
events in subtypes of major depressive disorder. Compr
Psychiatry 2001, 42:57-63.
32. Angst J, Angst F, Stassen HH: Suicide risk in patients with major
depressive disorder. J Clin Psychiatry 1999, 60:57-62.
33. Bennett KJ, Torrance GW, Boyle MH, Guscott R, Moran LA: Devel-
opment and testing of a utility measure for major, unipolar
depression (McSad). Qual Life Res 2000, 9:109-20.
34. Pyne JM, Patterson TL, Kaplan RM, Ho S, Gillin JC, Goldshan S, Grant
I: Preliminary longitudinal assessment of quality of life in
patients with major depression. Psychopharmacol Bull 1997,
33:23-9.
35. Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Koch WL, Grant I:
Assessment of quality of life of patients with major
depression. Psychiatr Serv 1997, 48:224-30.
36. Torrance GW, Feeny D: Utilities and quality-adjusted life years.
Int J Technol Assess Health Care 1989, 5:559-75.
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
Page 8 of 8
(page number not for citation purposes)
37. Revicki DA, Kaplan RM: Relationship between psychometric
and utility-based approaches to the measurement of health-
related quality of life. Qual Life Res 1993, 2:477-87.
38. Apolone G, De Carli G, Brunetti M, Garattini S: Health-related
quality of life (HR-QOL) and regulatory issues. An assess-
ment of the EMEA recommendations on the use of HR-QOL
measures in drug approval. Pharmacoeconomics 2001, 19:187-95.
39. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L,
Katon W, Wagner EH: Initial antidepressant choice in primary
care: effectiveness and cost of fluoxetine versus tricyclic
antidepressants. JAMA 1996, 275:1897-902.
40. Gold MR, Siegal JE, Russell LB, Weinstein MC, eds: Cost-Effective-
ness in Health and Medicine. New York: Oxford University Press;
1996. 
